Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Tenaya Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -148.56%, a change of -48.77% year-over-year.
Tenaya Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -78.17%, a change of 10.42% year-over-year.
Tenaya Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -73.50%, a change of 46.18% year-over-year.
Tenaya Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -113.74%, a change of -9.64% year-over-year.
Tenaya Therapeutics, Inc. roe for fiscal 2025 was -73.50%, a change of 46.18% from fiscal 2024.
Tenaya Therapeutics, Inc. roe for fiscal 2024 was -119.68%, a change of -30.68% from fiscal 2023.
Tenaya Therapeutics, Inc. roe for fiscal 2023 was -89.00%, a change of -38.19% from fiscal 2022.
Tenaya Therapeutics, Inc. roe for fiscal 2022 was -50.81%, a change of -24.70% from fiscal 2021.